Table 1.
Baseline characteristics of HCC patients.
| Variables | Total (n=213) |
HBV reactivation (n=16) |
Non-reactivation (n=197) |
P value |
|---|---|---|---|---|
| Age, years | 51.4 ± 10.4 | 50.3 ± 11.5 | 51.5 ± 10.3 | 0.666 |
| Sex | 1.000 | |||
| Male | 194 (91.1) | 15 (93.8) | 179 (90.9) | |
| Female | 19 (8.9) | 1 (6.3) | 18 (9.1) | |
| History of alcoholism | 0.997 | |||
| Yes | 60 (28.2) | 4 (25) | 56 (28.4) | |
| No | 153 (71.8) | 12 (75) | 141 (71.6) | |
| Antiviral prophylaxis | <0.001 | |||
| Yes | 181 (85) | 9 (56.3) | 172 (87.3) | |
| No | 32 (15) | 7 (43.7) | 25 (12.7) | |
| HBsAg | 1.000 | |||
| Seropositive | 190 (89.2) | 14 (87.5) | 176 (89.3) | |
| Seronegative | 23 (10.8) | 2 (12.5) | 21 (10.7) | |
| HBeAg | 0.605 | |||
| Seropositive | 44 (20.7) | 2 (12.5) | 42 (21.3) | |
| Seronegative | 169 (79.3) | 14 (87.5) | 155 (78.7) | |
| ECOG PS | 0.540 | |||
| 0 | 53 (24.9) | 5 (31.3) | 48 (24.4) | |
| 1-2 | 160 (75.1) | 11 (68.7) | 149 (75.6) | |
| Child Pugh score | 0.930 | |||
| 5 | 130 (61) | 9 (56.3) | 121(61.4) | |
| 6 | 60 (28.2) | 5 (31.3) | 55 (27.9) | |
| 7 | 18 (8.5) | 2 (12.5) | 16 (8.1) | |
| 8 | 5 (2.3) | 0 | 5 (2.6) | |
| ALBI grade | 0.790 | |||
| I | 118 (55.4) | 10 (62.5) | 108 (54.8) | |
| II | 93 (43.7) | 6 (37.5) | 87 (44.2) | |
| III | 2 (0.9) | 0 | 2 (1) | |
| Cirrhosis | 0.972 | |||
| Yes | 134 (62.9) | 10 (62.5) | 124 (62.9) | |
| No | 79 (37.1) | 6 (37.5) | 73 (37.1) | |
| Tumor diameter (cm) | 11.3 ± 4.4 | 12.8 ± 3.1 | 11.1 ± 4.5 | 0.158 |
| Tumor number | 1.000 | |||
| Single | 37 (17.4) | 3 (18.8) | 34 (17.3) | |
| Multiple | 176 (82.6) | 13 (81.3) | 163 (82.7) | |
| PVTT classification | 0.604 | |||
| Vp2 | 37 (17.4) | 3 (18.8) | 34 (17.3) | |
| Vp3 | 77 (36.1) | 5 (31.3) | 72 (36.5) | |
| Vp4 | 67 (31.5) | 7 (43.8) | 60 (30.5) | |
| No | 32 (15) | 1 (6.3) | 31 (15.7) | |
| Extra−hepatic metastasis | 0.981 | |||
| Yes | 147 (69) | 11 (68.8) | 136 (69) | |
| No | 66 (31) | 5 (31.3) | 61 (31) | |
| HBV DNA, IU/ml | <0.001 | |||
| Undetectable | 67 (31.5) | 12 (75) | 55 (27.9) | |
| Detectable | 146 (68.5) | 4 (25) | 142 (72.1) | |
| ≥ 2000 | 84 (57.5) | 0 | 84 (59.2) | 0.031 |
| <2000 | 62 (42.5) | 4 (100) | 58 (40.8) | |
| AFP, ng/ml | 32045(0.9-121000) | 27832 (46-121000) | 2084 (0.9-121000) | 0.166 |
| ALT, IU/L | 53.3 ± 41.2 | 50 ± 26.9 | 53.5 ± 42.2 | 0.745 |
| AST, IU/L | 99.3 ± 111.4 | 91.7 ± 75.8 | 99.9 ± 113.9 | 0.779 |
| Albumin, g/L | 40.8 ± 4.7 | 40.5 ± 5.7 | 40.9 ± 4.7 | 0.762 |
| TBil, μmol/L | 22.1 ± 26.4 | 18.5 ± 11.7 | 22.4 ± 27.2 | 0.571 |
| WBC, ×109/L | 7.8 ± 3.6 | 8.2 ± 2.6 | 7.8 ± 3.7 | 0.621 |
| Hemoglobin, g/L | 142.6 ± 23.3 | 142.4 ± 20.6 | 142.6 ± 23.6 | 0.978 |
| Platelet, ×109/L | 251.5 ± 109.9 | 267 ± 73.8 | 250.2 ± 112.5 | 0.557 |
| Cycles of HAIC | 4(2-8) | 4 (2-8) | 4 (2-6) | 0.927 |
| PD1s category | 0.765 | |||
| Pembrolizumab | 13 (6.1) | 1 (6.3) | 12 (6.1) | |
| Sintilimab | 86 (40.4) | 5 (31.3) | 81 (41.1) | |
| Toripalimab | 61 (28.6) | 6 (37.5) | 55 (27.9) | |
| Camrelizumab | 10 (4.7) | 0 | 10 (5.1) | |
| Tislelizumab | 43 (20.2) | 4 (25) | 39 (19.8) |
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; ECOG PS Eastern Cooperative Oncology Group performance status; ALBI grade, Albumin-Bilirubin grade; PVTT, portal vein tumor thrombosis; DNA, deoxyribonucleic acid; AFP alpha−fetoprotein, ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; WBC, white blood cell; HAIC hepatic arterial infusion chemo−therapy; PD1s, programmed death receptor-1 inhibitors.